Analysis of Jacobio Presents Pre-clinical Data of Pan-KRAS Inhibitor JAB-23E73 at AACR-NCI-EORTC International Conference - aVenture Research
PRNewswire
Jacobio Presents Pre-clinical Data of Pan-KRAS Inhibitor JAB-23E73 at AACR-NCI-EORTC International Conference
Jacobio Pharma presented pre-clinical data of its internally discovered pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The compound is a highly potent pan-KRAS (ON/OFF) inhibitor with strong selectivity sparing HRAS and NRAS, showing superior antitumor activity across multiple KRAS-driven cancer models, tumor regression without significant body weight loss, and favorable oral pharmacokinetics. Phase I trials of JAB-23E73 are ongoing in China and the United States for advanced solid tumors with KRAS alterations.
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.